Poxel SA
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the tr… Read more
Market Cap & Net Worth: Poxel SA (POXEL)
Poxel SA (PA:POXEL) has a market capitalization of $13.77 Million (€13.42 Million) as of March 18, 2026. Listed on the PA stock exchange, this France-based company holds position #28485 globally and #287 in its home market, demonstrating a 0.40% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Poxel SA's stock price €0.25 by its total outstanding shares 53663304 (53.66 Million).
Poxel SA Market Cap History: 2015 to 2026
Poxel SA's market capitalization history from 2015 to 2026. Data shows change from $729.31 Million to $13.85 Million (-29.18% CAGR).
Index Memberships
Poxel SA is a constituent of 6 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
CAC Mid & Small
CACMS
|
$47.81 Billion | 0.02% | #65 of 119 |
|
CAC Small90
CACS
|
$12.04 Billion | 0.08% | #41 of 64 |
|
CAC All-Tradable
CACT
|
$485.02 Billion | 0.00% | #79 of 179 |
|
CAC All-Tradable Net Total Return
CACTN
|
$485.02 Billion | 0.00% | #79 of 179 |
|
CAC All Tradable Gross Total Return
CACTR
|
$485.02 Billion | 0.00% | #79 of 179 |
|
CAC Health Care
FRHC
|
$71.02 Billion | 0.01% | #16 of 36 |
Weight: Poxel SA's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Poxel SA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Poxel SA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.15x
Poxel SA's market cap is 1.15 times its annual revenue
1742.66x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $729.31 Million | $59.65K | -$12.24 Million | 12226.50x | N/A |
| 2016 | $383.93 Million | $70.27K | -$24.48 Million | 5464.10x | N/A |
| 2017 | $361.90 Million | $5.29 Million | -$22.69 Million | 68.41x | N/A |
| 2018 | $280.38 Million | $74.61 Million | $13.53 Million | 3.76x | 20.73x |
| 2019 | $672.02 Million | $26.56 Million | -$25.74 Million | 25.30x | N/A |
| 2020 | $350.33 Million | $6.81 Million | -$31.86 Million | 51.47x | N/A |
| 2021 | $270.79 Million | $13.40 Million | -$23.76 Million | 20.21x | N/A |
| 2022 | $51.78 Million | $674.00K | -$31.40 Million | 76.82x | N/A |
| 2023 | $30.35 Million | $1.98 Million | -$35.09 Million | 15.32x | N/A |
| 2024 | $7.63 Million | $6.64 Million | -$18.30 Million | 1.15x | N/A |
Competitor Companies of POXEL by Market Capitalization
Companies near Poxel SA in the global market cap rankings as of March 18, 2026.
Key companies related to Poxel SA by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Poxel SA Historical Marketcap From 2015 to 2026
Between 2015 and today, Poxel SA's market cap moved from $729.31 Million to $ 13.85 Million, with a yearly change of -29.18%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €13.85 Million | +7.48% |
| 2025 | €12.89 Million | +68.83% |
| 2024 | €7.63 Million | -74.85% |
| 2023 | €30.35 Million | -41.38% |
| 2022 | €51.78 Million | -80.88% |
| 2021 | €270.79 Million | -22.70% |
| 2020 | €350.33 Million | -47.87% |
| 2019 | €672.02 Million | +139.69% |
| 2018 | €280.38 Million | -22.53% |
| 2017 | €361.90 Million | -5.74% |
| 2016 | €383.93 Million | -47.36% |
| 2015 | €729.31 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Poxel SA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $13.77 Million USD |
| MoneyControl | $13.77 Million USD |
| MarketWatch | $13.77 Million USD |
| marketcap.company | $13.77 Million USD |
| Reuters | $13.77 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.